Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celcuity Inc CELC

Healthcare Biotechnology
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes... see more

Recent & Breaking News (NDAQ:CELC)

Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

Business Wire March 16, 2021

Celcuity Announces Closing of Common Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

Accesswire March 1, 2021

Celcuity Prices Upsized Public Offering of Common Stock

Accesswire February 24, 2021

Celcuity Announces Proposed Public Offering of Common Stock

Accesswire February 22, 2021

Celcuity Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Accesswire February 16, 2021

Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2020 Financial Results and Conference Call

Accesswire February 1, 2021

Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

Business Wire January 27, 2021

Celcuity to Present at the B. Riley Oncology Investor Conference

Business Wire January 19, 2021

Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma Biotechnology

Accesswire December 23, 2020

Celcuity Reports Third Quarter 2020 Financial Results and Recent Business Highlights

Accesswire November 9, 2020

Celcuity Inc. Schedules Release of Third Quarter 2020 Financial Results and Conference Call

Accesswire October 26, 2020

Celcuity to Present at the LD Micro 500 Investor Conference

Accesswire August 27, 2020

Celcuity Reports Second Quarter 2020 Financial Results and Recent Business Highlights

Accesswire August 10, 2020

Celcuity Inc. Schedules Release of Second Quarter 2020 Financial Results and Conference Call

Accesswire July 24, 2020

Celcuity Hosting Call on CELsignia Pathway Activity Test for Ovarian Cancer

Accesswire July 1, 2020

Celcuity Presents Data at AACR Annual Meeting for CELsignia Pathway Activity Test for Ovarian Cancer

Accesswire June 22, 2020

Celcuity Reports First Quarter 2020 Financial Results and Recent Business Highlights

Accesswire May 7, 2020

Celcuity Inc. Schedules Release of First Quarter 2020 Financial Results and Conference Call

Accesswire April 23, 2020

Celcuity Reports Fourth Quarter and Full Year 2019 Financial Results

Accesswire March 12, 2020

Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2019 Financial Results and Conference Call

Accesswire February 27, 2020